Effects of Artificial Intelligence-Derived Body Composition on Kidney Graft and Patient Survival in the Eurotransplant Senior Program

Nick Lasse Beetz 1,2,*; Dominik Geisel 1; Seyd Shnayien 1; Timo Alexander Auer 1,3,*; Brigitta Globke 3,4; Robert Öllinger 4; Tobias Daniel Trippel 2,5; Thomas Schachtner 6; and Uli Fehrenbach 1,*

Abstract: The Eurotransplant Senior Program allocates kidneys to elderly transplant patients. The aim of this retrospective study is to investigate the use of computed tomography (CT) body composition using artificial intelligence (AI)-based tissue segmentation to predict patient and kidney transplant survival. Body composition at the third lumbar vertebra level was analyzed in 42 kidney transplant recipients. Cox regression analysis of 1-year, 3-year, and 5-year patient survival, 1-year, 3-year and 5-year uncensored kidney transplant survival was performed. First, the body mass index (BMI), psoas muscle index (PMI), skeletal muscle index (SMI), visceral adipose tissue (VAT), and subcutaneous adipose tissue (SAT) served as independent variates. Second, the cut-off values for sarcopenia and obesity served as independent variates. The 1-year uncensored and censored kidney transplant survival was influenced by reduced PMI (p = 0.02 and p = 0.03, respectively) and reduced SMI (p = 0.01 and p = 0.03, respectively); 3-year uncensored kidney transplant survival was influenced by increased VAT (p = 0.04); and 3-year censored kidney transplant survival was influenced by reduced SMI (p = 0.05). Additionally, sarcopenia influenced 1-year uncensored kidney transplant survival (p = 0.05), whereas obesity influenced 3-year and 5-year uncensored kidney transplant survival. In summary, AI-based body composition analysis may aid in predicting short- and long-term kidney transplant survival.

Keywords: kidney transplant; transplantation; Eurotransplant Senior Program (ESP); body composition; computed tomography (CT); artificial intelligence (AI)

1. Introduction

In an aging society, frailty is one of the largest challenges facing healthcare as patients who suffer from sarcopenia, cachexia, and obesity are at risk for prolonged hospitalization, perioperative complications, and poorer overall survival [1,2]. Therefore, appropriate identification of these patients at risk is desirable. Unlike the body mass index (BMI), artificial intelligence (AI)-based analysis of body composition can differentiate the relative proportions of various tissues using muscle and adipose tissue parameters including the skeletal muscle index (SMI), psoas muscle index (PMI), visceral adipose tissue (VAT), and
subcutaneous adipose tissue (SAT) [3]. Additionally, body composition analysis can be used to detect sarcopenia, which is defined as the presence of low muscle mass using sex specific cut-off values, and sarcopenic obesity, which is defined as the combined presence of both sarcopenia and obesity [4]. The metabolic information derived from this kind of individual body composition analysis can identify frail patients (e.g., patients with sarcopenic obesity who have a normal BMI with reduced muscle mass and severe obesity) [5].

Kidney transplant recipients aged 65 years and older with end-stage renal disease benefit from being allocated a transplant kidney in the Eurotransplant Senior Program (ESP) by having a better survival rate and quality of life compared with that from hemodialysis treatment [6,7]. Despite the survival benefit, kidney transplant recipients still have a high mortality rate compared with that of the general population [8]. Organ shortage and perioperative morbidity necessitate the careful workup of potential kidney transplant recipients to ensure an optimal outcome. Aside from cardiovascular disease, arterial hypertension, and diabetes mellitus, preoperative frailty has been shown to be associated with a higher risk of death and delayed graft function [9,10]. Additionally, surgical complications and delayed graft function are more common in obese patients [11,12].

Especially in older and diabetic patients, a computed tomography (CT) scan of the abdomen and pelvis is routinely performed to detect iliac calcification as peripheral vascular disease increases the risk of transplant ischemia [13]. In general, the information gained from the CT is only used to plan optimal graft positioning [14]. However, these imaging studies could easily be used for additional preoperative analysis of body composition as well [15]. CT body composition parameters have been identified as outcome predictors in many cardiovascular and oncological diseases. For example, body composition has been reported to predict life-threatening progression of aortic enlargement in Marfan syndrome or severe complications, prolonged hospitalization, and overall survival in esophageal cancer [16,17]. Moreover, abdominal obesity has been found to predict coronary heart disease, and the PMI seems to predict outcomes in patients undergoing transcatheter aortic valve implantation [18,19].

The hypothesis of this study is that AI-based body composition parameters may influence 1-year, 3-year and 5-year patient survival, 1-year, 3-year and 5-year censored kidney transplant survival, and 1-year, 3-year and 5-year uncensored kidney transplant survival in elderly kidney transplant recipients from the ESP. As initial evaluation of older candidates for kidney transplant routinely includes CT examinations of the abdomen and pelvis, we used the CT data for a retrospective AI-based analysis of individual body compositions to identify possible imaging predictors and imaging risk factors for patient and transplant survival.

2. Materials and Methods

2.1. Study Design

In this single-center study, we analyzed body composition in a retrospective dataset of kidney transplant recipients from the ESP who had undergone a CT scan of the abdomen and pelvis for initial evaluation before transplantation. The study was approved by the institutional review board and performed in compliance with the Declaration of Helsinki.

2.2. Patient Population and Characteristics

Kidney transplant recipients from the ESP aged 65 years and older were included in this study if they had undergone CT of the lower abdomen and pelvis for initial evaluation. They were referred for CT from the Department of Surgery or the Department of Nephrology. All patients included underwent solitary kidney transplantation at our university transplant center between 2011 and 2016. Exclusion criteria were patients without CT scans prior to surgery and aged <65 years. Additionally, patients were excluded if their CT images did not include the third lumbar vertebra.
2.3. Baseline Data

Two patients had to be excluded because the CT scan of their lower abdomen and pelvis did not include the third lumbar vertebra. A total of 42 patients with a mean age of 69 ± 4 years at the time of transplantation (range: 65 to 80 years) were included in this study: 13 women and 29 men. The mean weight was 78 ± 14 kg, and mean height was 171 ± 8 cm. BMI was calculated using the following formula: 
\[ \text{BMI} = \frac{\text{weight}}{\text{height}^2} \, (\text{kg/m}^2) \]; mean BMI was 27 ± 7.

Almost all patients received basiliximab for induction and Tac/MMF/MP for maintenance of immunosuppression. One patient received rATG for induction and another patient received CyA/everolimus/MP for permanent immunosuppression. Further clinical characteristics of kidney transplant recipients and donor organs are compiled in Table 1.

Table 1. Clinical characteristics of kidney transplant recipients. HLA = human leukocyte antigen. IL-2 = interleukin 2. IS = immunosuppression. KDRI = kidney donor risk index. KDPI = kidney donor profile index. PKD = polycystic kidney disease. * Median ± standard deviation.

| Total (n = 42) |
|----------------|
| **Recipient Characteristics** |
| Recipient age, years * | 69 ± 4 |
| Renal disease, n (%) |
| Diabetic | 10 (24%) |
| Hypertensive | 4 (10%) |
| PKD | 5 (12%) |
| Glomerular disease | 9 (21%) |
| Others/Unknown | 14 (33%) |
| Recipient, female sex, n (%) | 17 (40%) |
| Deceased donation, n (%) | 42 (100%) |
| Living donation, n (%) | 0 (0%) |
| Cold ischemia time, minutes * | 581 (241–1076) |
| **Immunosuppression** |
| Induction IS, n (%) |
| IL-2 receptor blockade | 41 (98%) |
| Lymphocyte depletion | 1 (2%) |
| Maintenance IS, n (%) |
| MMF/MPA | 42 (100%) |
| Tacrolimus | 41 (98%) |
| Ciclosporine | 1 (2%) |
| Azathioprin | 1 (2%) |
| Total HLA Mismatches * | 3.6 (0–6) |
| **Donor Characteristics** |
| Donor age, years | 69 ± 5 |
| Donor, female sex, n (%) | 31 (74%) |
| KDPI (%) | 97 ± 3 |
| KDRI | 2 ± 0.4 |

2.4. Data Collection, Follow-Up, and Endpoints

All data were retrieved from the patient records and clinical database. Thirty-one kidney transplant recipients attended aftercare at our university transplant center at 3-month intervals, and 11 kidney transplant recipients were followed up by local nephrologists or general practitioners. Follow-up rates at 1 year, 3 years, and 5 years after transplantation were 100%. Endpoints were defined as 1-year, 3-year, and 5-year patient survival and
1-year, 3-year, and 5-year censored transplant survival and uncensored (= not censored for death) transplant survival.

2.5. Body Composition Analysis

Available CT datasets acquired at the Department of Radiology and at external locations were used for analysis of body composition. Image segmentation was performed with an AI-based automated software tool using a convolutional neural network, U-net (Visage version 7.1, Visage Imaging GmbH, Berlin, Germany). The network consists of nine blocks: four down-sampling blocks, four up-sampling blocks, and one in between. The training data consisted of 200 axial CT images of the L3 level, and augmentation was applied during training to improve generalization of the network. Psoas muscle, skeletal muscle, visceral adipose tissue, and subcutaneous adipose tissue were automatically separated and coded with different colors. Automatic segmentation was checked by an experienced radiologist. In few cases, AI-based image segmentation was manually corrected, for example, when hypodense stool in the intestine was misinterpreted as body fat. The software automatically calculated the area in square centimeters (cm²) and density in Hounsfield units of each segmented tissue class. Areas of skeletal muscle, visceral adipose tissue (VAT), and subcutaneous adipose tissue (SAT) at L3 were derived for body composition analysis. The psoas muscle index (PMI) was calculated using the following formula: psoas muscle area (cm²)/body surface area (m²). The skeletal muscle index (SMI) was calculated using the following formula: skeletal muscle area (cm²)/body surface area (m²). Examples of AI-based automated analysis of body composition are shown in Figure 1.

![Figure 1](a) 65-year-old male kidney transplant recipient with a BMI of 27.7, PMI of 9.8, and SMI of 67.6. (b) 65-year-old male kidney transplant recipient with a BMI of 27.8, PMI of 3.9, and SMI of 44.4. Even though both patients are the same age and have almost the same BMI, their body composition parameters are considerably different. Each segmented tissue is coded with a different color: psoas muscle = purple, skeletal muscle (except psoas muscle) = green, visceral fat = dark green, blue = subcutaneous fat. Tissue density and area were automatically calculated using Visage version 7.1.

2.6. Induction and Maintenance Immunosuppression

The choice of induction therapy was based on immunologic risk. Kidney transplant recipients with a low immunologic risk received an interleukin-2 receptor blockade with basiliximab, and recipients with a high immunologic risk received lymphocyte-depleting induction with rATG. Primary immunosuppression consisted of a triple-drug combination of a calcineurin inhibitor (CNI), tacrolimus or cyclosporine, antimetabolite (mycophenolate mofetil (MMF), mycophenolic acid (MPA) or azathioprine), and steroids. Steroid treatment was tapered over 8 weeks to a dose of 4 mg methylprednisolone/day.
2.7. Statistical Analysis

For analysis of 1-year, 3-year, and 5-year patient survival and kidney transplant survival, multivariate Cox regression was performed, and \( p \leq 0.05 \) was considered to indicate a significant difference. Kaplan–Meier curves were plotted for 3-year and 5-year uncensored kidney transplant survival and log-rank testing was performed. All data analyses were performed using IBM SPSS Statistics version 27 (International Business Machines Corporation, IBM, Armonk, NY, USA).

For each outcome endpoint, including 1-year, 3-year, and 5-year patient survival and 1-year, 3-year, and 5-year censored transplant survival and 1-year, 3-year, and 5-year uncensored transplant survival, the dependent variant was defined as death of the patient or kidney transplant. First, BMI and the AI-derived body composition parameters PMI, SMI, VAT, and SAT served as independent variants. Second, cut-offs for sarcopenia, defined as SMI \( \leq 38.5 \, \text{cm}^2/\text{m}^2 \) in women and SMI \( \leq 52.4 \, \text{cm}^2/\text{m}^2 \) in men, and obesity (BMI \( \geq 30 \)), were used as independent variates. Age as a possible confounder was excluded. Sex was included by defining specific cut-offs for men and women [20].

3. Results

3.1. AI-Based Body Composition Parameters and Cut-Offs

All AI-based body composition parameters were derived at the third lumbar vertebra level. The mean PMI was \( 5.4 \pm 1.9 \, \text{cm}^2/\text{m}^2 \), and the mean SMI was \( 42.0 \pm 7.6 \, \text{cm}^2/\text{m}^2 \). The mean VAT was \( 203.0 \pm 123.3 \, \text{mm}^2 \), and SAT \( 204.7 \pm 91.2 \, \text{mm}^2 \). Thirteen patients (31%) had sarcopenia, 11 patients (26%) had obesity, and 5 patients (12%) had sarcopenic obesity. All results are compiled in Table 2.

| Body Composition Parameter | Value (± Standard Deviation) |
|----------------------------|-----------------------------|
| BMI                        | 27 ± 7                      |
| PMI (cm\(^2\)/m\(^2\))    | 5.4 ± 1.9                   |
| SMI (cm\(^2\)/m\(^2\))    | 42.0 ± 7.6                  |
| VAT (mm\(^2\))            | 203.0 ± 123.3               |
| SAT (mm\(^2\))            | 204.7 ± 91.2                |
| Sarcopenia                 | 31%                         |
| Obesity                    | 26%                         |
| Sarcopenic obesity         | 12%                         |

3.2. Cox Regression Analysis with BMI and AI-Derived Body Composition Parameters as Independent Variates

One-year, 3-year, and 5-year patient survival was not predicted by BMI or any AI-derived body composition parameter including PMI, SMI, VAT and SAT. All results are compiled in Table 3.

One-year censored kidney transplant survival was significantly predicted by a reduced PMI (\( p = 0.03 \)) and reduced SMI (\( p = 0.03 \)); 3-year censored kidney transplant survival was significantly predicted by a reduced SMI (\( p = 0.05 \)); but 5-year censored kidney transplant survival was not predicted by BMI or any AI-derived body composition parameter. All results are compiled in Table 4.

One-year uncensored kidney transplant survival was significantly predicted by a reduced PMI (\( p = 0.02 \)) and reduced SMI (\( p = 0.01 \)). In contrast, 3-year uncensored kidney transplant survival was significantly predicted by increased VAT (\( p = 0.04 \)), while 5-year uncensored kidney transplant survival was not predicted by BMI or any AI-derived body composition parameter. All results are compiled in Table 5.
Table 3. Cox regression analysis of 1-year, 3-year and 5-year patient survival with the variates BMI and AI-derived body composition parameters PMI, SMI, VAT and SAT. AI = artificial intelligence, BMI = body mass index, CI = confidence interval, PMI = psoas muscle index, SMI = skeletal muscle index, SAT = subcutaneous adipose tissue, VAT = visceral adipose tissue.

| Variate | 1-Year Patient Survival | 3-Year Patient Survival | 5-Year Patient Survival |
|---------|-------------------------|-------------------------|-------------------------|
|         | p-Value | Odds Ratio (CI) | p-Value | Odds Ratio (CI) | p-Value | Odds Ratio (CI) |
| BMI     | 0.44    | 1.03 (0.95–1.12) | 0.63    | 1.03 (0.92–1.14) | 0.28    | 1.05 (0.96–1.15) |
| PMI     | 0.64    | 1.09 (0.76–1.57) | 0.49    | 1.16 (0.76–1.75) | 0.40    | 1.17 (0.81–1.67) |
| SMI     | 0.94    | 1.00 (0.91–1.11) | 0.93    | 0.99 (0.89–1.11) | 0.97    | 1.00 (0.91–1.11) |
| VAT     | 1.00    | 1.00 (0.99–1.01) | 0.46    | 1.00 (0.99–1.01) | 0.70    | 1.00 (0.99–1.01) |
| SAT     | 0.91    | 1.00 (0.99–1.01) | 0.63    | 1.00 (0.99–1.01) | 0.99    | 1.00 (0.99–1.01) |

Table 4. Cox regression analysis of 1-year, 3-year and 5-year censored kidney transplant survival with the variates BMI and AI-derived body composition parameters PMI, SMI, VAT, and SAT. AI = artificial intelligence, BMI = body mass index, CI = confidence interval, PMI = psoas muscle index, SMI = skeletal muscle index, SAT = subcutaneous adipose tissue, VAT = visceral adipose tissue.

| Variate | 1-Year Censored Kidney Transplant Survival | 3-Year Censored Kidney Transplant Survival | 5-Year Censored Kidney Transplant Survival |
|---------|-------------------------------------------|-------------------------------------------|-------------------------------------------|
|         | p-Value | Odds Ratio (CI) | p-Value | Odds Ratio (CI) | p-Value | Odds Ratio (CI) |
| BMI     | 0.90    | 1.02 (0.79–1.31) | 0.37    | 1.07 (0.93–1.23) | 0.07    | 1.11 (0.99–1.26) |
| PMI     | 0.03    | 0.25 (0.07–0.89) | 0.23    | 0.62 (0.35–1.29) | 0.36    | 0.79 (0.47–1.31) |
| SMI     | 0.03    | 0.55 (0.35–0.75) | 0.05    | 0.75 (0.50–1.00) | 0.06    | 0.82 (0.65–1.00) |
| VAT     | 0.13    | 0.98 (0.96–1.01) | 0.07    | 1.01 (1.00–1.02) | 0.06    | 0.99 (0.98–1.00) |
| SAT     | 0.21    | 1.01 (0.99–1.03) | 0.16    | 1.00 (1.00–1.01) | 0.24    | 1.01 (1.00–1.01) |

Table 5. Cox regression analysis of 1-year, 3-year and 5-year uncensored kidney transplant survival with the variates BMI and AI-derived body composition parameters PMI, SMI, VAT and SAT. AI = artificial intelligence, BMI = body mass index, CI = confidence interval, PMI = psoas muscle index, SMI = skeletal muscle index, SAT = subcutaneous adipose tissue, VAT = visceral adipose tissue.

| Variate | 1-Year Uncensored Kidney Transplant Survival | 3-Year Uncensored Kidney Transplant Survival | 5-Year Uncensored Kidney Transplant Survival |
|---------|-------------------------------------------|-------------------------------------------|-------------------------------------------|
|         | p-Value | Odds Ratio (CI) | p-Value | Odds Ratio (CI) | p-Value | Odds Ratio (CI) |
| BMI     | 0.31    | 1.09 (0.79–1.31) | 0.21    | 1.07 (0.96–1.19) | 0.60    | 1.09 (1.00–1.18) |
| PMI     | 0.02    | 0.26 (0.08–0.84) | 0.23    | 0.76 (0.49–1.19) | 0.32    | 0.83 (0.58–1.20) |
| SMI     | 0.01    | 0.69 (0.46–0.92) | 0.06    | 0.99 (0.98–1.00) | 0.08    | 0.99 (0.99–1.00) |
| VAT     | 0.14    | 0.99 (0.98–1.00) | 0.04    | 1.13 (0.99–1.29) | 0.06    | 0.90 (0.80–1.00) |
| SAT     | 0.45    | 1.00 (0.99–1.02) | 0.20    | 1.00 (1.00–1.01) | 0.68    | 1.00 (0.99–1.01) |

3.3. Cox Regression Analysis with Sarcopenia and Obesity as Cut-Off Independent Variates

Cut-off values for sarcopenia and obesity did not influence 1-year, 3-year or 5-year patient survival. The results are compiled in Table 6.
### Table 6. Cox regression analysis of 1-year, 3-year and 5-year patient survival with cutoff values for sarcopenia and obesity. CI = confidence interval.

| Variate | 1-Year Patient Survival | 3-Year Patient Survival | 5-Year Patient Survival |
|---------|-------------------------|-------------------------|-------------------------|
|         | p-Value | Odds Ratio (CI) | p-Value | Odds Ratio (CI) | p-Value | Odds Ratio (CI) |
| Sarcopenia | 0.10 | 1.14 (1.01–2.48) | 0.76 | 1.82 (1.24–3.86) | 0.68 | 1.79 (1.26–2.40) |
| Obesity | 0.42 | 2.19 (0.33–14.7) | 0.24 | 2.12 (0.61–7.39) | 0.12 | 2.39 (0.79–7.23) |

Cut-off values for sarcopenia and obesity did not influence 1-year, 3-year or 5-year censored kidney transplant survival. The results are compiled in Table 7.

### Table 7. Cox regression analysis of 1-year, 3-year and 5-year censored kidney transplant survival with cutoff values for sarcopenia and obesity. CI = confidence interval.

| Variate | 1-Year Censored Kidney Transplant Survival | 3-Year Censored Kidney Transplant Survival | 5-Year Censored Kidney Transplant Survival |
|---------|-------------------------------------------|-------------------------------------------|-------------------------------------------|
|         | p-Value | Odds Ratio (CI) | p-Value | Odds Ratio (CI) | p-Value | Odds Ratio (CI) |
| Sarcopenia | 0.10 | 1.14 (1.01–2.42) | 0.10 | 1.28 (1.06–2.29) | 0.31 | 1.50 (1.13–2.90) |
| Obesity | 0.39 | 2.31 (0.34–15.6) | 0.23 | 2.53 (0.56–11.3) | 0.08 | 3.31 (0.86–12.7) |

Cut-off values for sarcopenia significantly predicted uncensored 1-year uncensored kidney transplant survival ($p = 0.05$), and the values for obesity significantly predicted 3-year and 5-year uncensored kidney transplant survival. The results are compiled in Table 8.

### Table 8. Cox regression analysis of 1-year, 3-year and 5-year uncensored kidney survival with cutoff values for sarcopenia and obesity. CI = confidence interval.

| Variate | 1-Year Uncensored Kidney Transplant Survival | 3-Year Uncensored Kidney Transplant Survival | 5-Year Uncensored Kidney Transplant Survival |
|---------|-------------------------------------------|-------------------------------------------|-------------------------------------------|
|         | p-Value | Odds Ratio (CI) | p-Value | Odds Ratio (CI) | p-Value | Odds Ratio (CI) |
| Sarcopenia | 0.05 | 1.19 (1.03–2.02) | 0.23 | 1.51 (1.17–2.53) | 0.28 | 1.60 (1.23–2.52) |
| Obesity | 0.15 | 3.11 (0.67–14.3) | 0.05 | 3.02 (1.01–9.04) | 0.02 | 2.95 (1.15–7.55) |

The influence of sarcopenia on 1-year uncensored kidney transplant survival and the influence of obesity on 5-year uncensored kidney transplant survival are shown in Kaplan–Meier curves (Figure 2). The log-rank showed the significant influence of sarcopenia and obesity ($p = 0.002$ and $p = 0.007$, respectively).
Cut-off values for sarcopenia significantly predicted uncensored 1-year uncensored kidney transplant survival ($p = 0.05$), and the values for obesity significantly predicted 3-year and 5-year uncensored kidney transplant survival. The results are compiled in Table 8.

The influence of sarcopenia on 1-year uncensored kidney transplant survival and the influence of obesity on 5-year uncensored kidney transplant survival are shown in Kaplan–Meier curves (Figure 2). The log-rank showed the significant influence of sarcopenia and obesity ($p = 0.002$ and $p = 0.007$, respectively).

Figure 2. (a) Graph showing that sarcopenia assessed by a routine pretransplant computed tomography (CT) scan may influence 1-year uncensored graft survival. Log rank test: $p = 0.002$. (b) Graph showing that obesity may influence 5-year uncensored graft survival. Log rank test: $p = 0.007$.

4. Discussion

In this retrospective study we evaluated the usefulness of artificial intelligence-based body composition analysis for predicting kidney transplant survival and recipient survival in the Eurotransplant Senior Program. Outcome endpoints were defined as 1-year, 3-year, and 5-year for patients and transplants. Body composition parameters were tested as possible outcome predictors by analyzing overall patient and transplant survival over a follow-up period of 5 years after kidney transplantation. For 1-year censored and uncensored transplant survival, we identified lower a PMI and SMI as significant predictors of graft loss. The 3-year uncensored kidney transplant survival was significantly influenced by higher VAT, whereas 3-year censored kidney transplant survival was significantly influenced by a lower SMI. Moreover, sarcopenia significantly predicted 1-year uncensored transplant survival. Long-term 3-year and 5-year survival analysis identified obesity as a significant
risk factor for uncensored transplant survival. In contrast, recipient survival was not significantly influenced by the BMI or any of the AI-derived body composition parameters.

Preoperative assessment of frailty in candidates for kidney transplantation was important as the availability of organs is limited. The BMI is a commonly used indicator of a patient’s fitness although it is an uncertain diagnostic index of obesity [21,22]. If a discrepancy between BMI and obesity is suspected, for example, in patients with sarcopenia and a normal BMI, a more sophisticated assessment is required [23]. Analysis of CT body composition at L3 was shown to allow objective measurement of a patient’s physical fitness [24,25]. In our study, 31% of patients were sarcopenic, which was detected by CT but not BMI. Interestingly, sarcopenia predicted transplant survival in the first year after kidney transplant but not 3-year or 5-year survival. This may have been attributable to the fact that sarcopenia is associated with postoperative complications, which may affect early transplant survival [26]. Three to five years after kidney transplant, the patient’s fitness may have recovered and no longer influenced the outcome [27].

In the past, obesity was considered a risk factor because obese kidney recipients had a higher rate of graft loss and all-cause mortality. Since then, Nicoletto et al. have reported the same graft and patient survival rates for obese and nonobese kidney recipients [28]. Tzvetanov et al. have shown that kidney transplantation is also possible in obese patients [29]. Our results demonstrated that the body composition parameters VAT and SAT, both reflecting the amount of adipose tissue and the cut-off value for obesity, did not aid in risk stratification for overall patient survival. However, VAT emerged as a significant risk factor for 3-year uncensored kidney transplant survival. Consistent with our findings, a recent study of Manabe et al. showed that the visceral fat area is significantly associated with the progression of kidney disease [30]. Moreover, obesity significantly influenced 3-year and 5-year uncensored kidney transplant survival.

The results of our study matched our clinical experience: frailty—represented by the AI-derived body composition parameters SMI/PMI and sarcopenia cut-off value—is an important perioperative risk factor, whereas overweight—represented by the AI-derived body composition parameter VAT and obesity cut-off value—becomes much more relevant for long-term outcomes as it is associated with many cardiovascular diseases. We attributed the differences between censored and uncensored kidney transplant survival to the fact that the latter includes the patient’s death, which may have been influenced by frailty and overweight.

Unlike transplant survival, short- and long-term patient survival was not predicted by any AI-derived body composition parameter or BMI, nor did these parameters aid in risk stratification for overall patient survival. A possible explanation might be that especially older kidney transplant recipients suffered from comorbidities including coronary artery disease, diabetes mellitus, and hypertension, all of which are risk factors for mortality [31,32].

Body composition analysis has been found to be a useful indicator for prognosis and risk stratification, particularly in patients with cardiovascular and malignant diseases [5,33]. Both sarcopenia and sarcopenic obesity are risk factors in cardiovascular disease but also associated with unfavorable outcomes in malignancies and with prolonged postoperative recovery [34–37]. CT allows for reliable analysis of body composition from a single axial image acquired at the L3 level [15,38]. Most software tools for non-AI-based body composition analysis, such as SliceOmatic or Horos, use pixel thresholding with region growing [39]. However, these manual or semiautomatic segmentation procedures for CT datasets are time consuming and have therefore been limited to smaller patient populations. The postprocessing time of these datasets is dramatically decreased when AI-based body composition analysis is used [40]. In our study, we used an established, fully automatic AI-based software tool that provided valuable metabolic information without additional radiation exposure. In this study, we described the influence of AI-based analysis of body composition parameters on short-term and long-term recipient and transplant survival in older kidney transplant recipients for the first time.
Our study was limited by the use of a retrospective dataset and a relatively small study population. Elderly kidney transplant recipients suffer especially from multiple comorbidities, which may have influenced both graft survival and patient survival as well.

5. Conclusions

The survival of kidney recipients cannot be predicted by AI-derived body composition parameters. However, AI-based body composition analysis is useful for predicting short- and long-term kidney transplant survival: the body composition parameters PMI and SMI, both of which represent muscle tissue, and sarcopenia predict 1-year transplant survival, whereas obesity and VAT, which represents fat tissue, predict 3-year and 5-year kidney transplant survival. Therefore, AI-based analysis of body composition may aid in identifying patients at risk who require special care and individualized decision making to achieve optimal outcomes.

Author Contributions: Conceptualization, N.L.B. and T.S.; methodology, N.L.B. and U.F.; software, N.L.B. and U.F.; validation, U.F. and N.L.B.; formal analysis, D.G., U.F. and N.L.B.; investigation, T.S. and N.L.B.; resources, D.G.; data curation, N.L.B.; writing—original draft preparation, N.L.B.; writing—review and editing, B.G., R.Ö., S.S., T.D.T. and T.A.A.; visualization, N.L.B.; supervision, U.F. and T.S.; project administration, N.L.B. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding. We acknowledge support from the German Research Foundation (DFG) and the Open Access Publication Fund of Charité—Universitätsmedizin Berlin.

Institutional Review Board Statement: The study was conducted according to the guidelines of the Declaration of Helsinki and was approved by the Institutional Review Board of Charité Berlin (internal registration number: EA4/152/20, 21 August 2020).

Informed Consent Statement: Patient consent was waived due to the retrospective study design.

Data Availability Statement: The data presented in this study are available on request from the corresponding author.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Newman, A.B.; Lee, J.S.; Visser, M.; Goodpaster, B.H.; Kritchevsky, S.B.; Tylavsky, F.A.; Nevitt, M.; Harris, T.B. Weight change and the conservation of lean mass in old age: The Health, Aging and Body Composition Study. Am. J. Clin. Nutr. 2005, 82, 872–878. [CrossRef]

2. Prado, C.M.; Wells, J.C.; Smith, S.R.; Stephan, B.C.; Siervo, M. Sarcopenic obesity: A Critical appraisal of the current evidence. Clin. Nutr. 2012, 31, 583–601. [CrossRef]

3. Beetz, N.L.; Maier, C.; Segger, L.; Shnayien, S.; Trippel, T.D.; Geisel, D.; Fehrenbach, U. First PACS-integrated, artificial intelligence-based software tool for rapid and fully automatic analysis of body composition from CT in clinical routine. JCSM Clin. Rep. 2021, 7, 3–11. [CrossRef]

4. Cruz-Jentoft, A.J.; Baeyens, J.P.; Bauer, J.M.; Boirie, Y.; Cederholm, T.; Landi, F.; Martin, F.C.; Michel, J.P.; Rolland, Y.; Schneider, S.M.; et al. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. Age Ageing 2010, 39, 412–423. [CrossRef]

5. Feliciano, E.M.C.; Popuri, K.; Cobzas, D.; Baracos, V.E.; Beg, M.F.; Khan, A.D.; Ma, C.; Chow, V.; Prado, C.M.; Xiao, J.; et al. Evaluation of automated computed tomography segmentation to assess body composition and mortality associations in cancer patients. J. Cachexia Sarcopenia Muscle 2020, 11, 1258–1269. [CrossRef]

6. Langer, R.M.; Cohen, B.; Rahmel, A. History of eurotransplant. Transplant. Proc. 2012, 44, 2130–2131. [CrossRef]

7. Fabrizii, V.; Winkelmayer, W.C.; Klausner, R.; Kletzmayr, J.; Säemann, M.D.; Steininger, R.; Kramar, R.; Hörl, W.H.; Kovarik, J. Patient and graft survival in older kidney transplant recipients: Does age matter? J. Am. Soc. Nephrol. 2004, 15, 1052–1060. [CrossRef]

8. Schachtner, T.; Otto, N.M.; Reinke, P. Two decades of the Eurotransplant Senior Program: The gender gap in mortality impacts patient survival after kidney transplantation. Clin. Kidney J. 2020, 13, 1091–1100. [CrossRef]

9. Garrowzik-Wang, J.M.; Govindan, P.; Grinnan, J.W.; Liu, M.; Ali, H.M.; Chakraborty, A.; Jain, V.; Ros, R.L.; James, N.T.; Kucirka, L.M.; et al. Frailty and delayed graft function in kidney transplant recipients. Arch. Surg. 2012, 147, 190–193. [CrossRef]

10. Glanton, C.W.; Kao, T.C.; Cruss, D.; Agooda, L.Y.; Abbott, K.C. Impact of renal transplantation on survival in end-stage renal disease patients with elevated body mass index. Kidney Int. 2003, 63, 647–653. [CrossRef]
11. Kasiske, B.L.; Cangro, C.B.; Harirhan, S.; Hricik, D.E.; Kerman, R.H.; Roth, D.; Rush, D.N.; Vazquez, M.A.; Weir, M.R. The evaluation of renal transplantation candidates: Clinical practice guidelines. *Am. J. Transplant.* 2001, 1 (Suppl. 2), 3–95. [CrossRef]

12. Weissenbacher, A.; Jara, M.; Ulmer, H.; Biebl, M.; Bösmüller, C.; Schneebberger, S.; Mayer, G.; Pratschke, J.; Öllinger, R. Recipient and donor body mass index as important risk factors for delayed kidney graft function. *Transplantation 2012*, 93, 524–529. [CrossRef]

13. Mákosalo, H.; Lepántalo, M.; Halme, L.; Lund, T.; Peltonen, S.; Salmela, K.; Ahonen, J. Peripheral arterial disease as a predictor of outcome after renal transplantation. *Transpl. Int. 1998*, 11 (Suppl. 1), S140–S143. [CrossRef]

14. Werlin, E.C.; Braun, H.J.; Walker, J.P.; Freise, J.E.; Amara, D.; Liu, L.H.; Mello, A.; Tavakol, M.; Stock, P.G.; Hiramoto, J.S. Utility of a Simplified Iliac Artery Calcium Scoring System to Guide Perioperative Management for Renal Transplantation. *Front. Med. 2021*, 8, 608353. [CrossRef]

15. Gibson, D.J.; Burden, S.T.; Strauss, B.J.; Todd, C.; Lal, S. The role of computed tomography in evaluating body composition and the influence of reduced muscle mass on outcome in abdominal malignancy: A systematic review. *Eur. J. Clin. Nutr. 2015*, 69, 1079–1086. [CrossRef]

16. Beetz, N.L.; Maier, C.; Shnayien, S.; Trippel, T.D.; Gehle, P.; Fehrenbach, U.; Geisel, D. Artificial intelligence-based analysis of body composition in Marfan: Skeletal muscle density and psoas muscle index predict aortic enlargement. *J. Cachexia Sarcopenia Muscle 2021*, 12, 993–999. [CrossRef]

17. Fehrenbach, U.; Wueresch, T.; Gabriel, P.; Segger, L.; Yamaguchi, T.; Auer, T.A.; Beetz, N.L.; Denecke, C.; Kröll, D.; Raakow, J.; et al. CT Body Composition of Sarcopenia and Sarcopenic Obesity: Predictors of Postoperative Complications and Survival in Patients with Locally Advanced Esophageal Adenocarcinoma. *Cancers 2021*, 13, 2921. [CrossRef]

18. Kofler, M.; Reinstadler, S.J.; Mayr, A.; Stastny, L.; Reindl, M.; Dumfarth, J.; Dachs, T.M.; Wachter, K.; Rustenbach, C.J.; Friedrich, G.; et al. Prognostic implications of psoas muscle area in patients undergoing transsacetheter aortic valve implantation. *Eur. J. Cardiothorac. Surg. 2019*, 55, 210–216. [CrossRef]

19. Canoy, D.; Boekholdt, S.M.; Wareham, N.; Luben, R.; Welch, A.; Bingham, S.; Buchan, I.; Day, N.; Khaw, K.T. Body fat distribution and risk of coronary heart disease in men and women in the European Prospective Investigation Into Cancer and Nutrition in Norfolk cohort: A population-based prospective study. *Circulation 2007*, 116, 2933–2943. [CrossRef]

20. Prado, C.M.; Lieffers, J.R.; McCargar, L.J.; Reiman, T.; Sawyer, M.B.; Martin, L.; Baracos, V.E. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: A population-based study. *Lancet Oncol. 2008*, 9, 629–635. [CrossRef]

21. McAdams-DeMarco, M.A.; Law, A.; King, E.; Orandi, B.; Salter, M.; Gupta, N.; Chow, E.; Alachkar, N.; Desai, N.; Varadhan, R.; et al. Frailty and mortality in kidney transplant recipients. *Am. J. Transplant. 2015*, 15, 149–154. [CrossRef] [PubMed]

22. Nastasi, A.J.; McAdams-DeMarco, M.A.; Schrack, J.; Ying, H.; Olorundare, I.; Warsame, F.; Mountford, A.; Hauguen, C.E.; Fernández, M.G.; Norman, S.P.; et al. Pre-Kidney Transplant Lower Extremity Impairment and Post-Kidney Transplant Mortality. *Am. J. Transplant. 2018*, 18, 189–196. [CrossRef] [PubMed]

23. Wellens, R.I.; Roche, A.F.; Khamis, H.J.; Jackson, A.S.; Pollock, M.L.; Siervogel, R.M. Relationships between the Body Mass Index and body composition. *Obes. Res. 1996*, 4, 35–44. [CrossRef] [PubMed]

24. Mourtzakis, M.; Prado, C.M.; Lieffers, J.R.; Reiman, T.; McCargar, L.J.; Baracos, V.E. A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. *Appl. Physiol. Nutr. Metab. 2008*, 33, 997–1006. [CrossRef]

25. Fearon, K.; Strasser, F.; Anker, S.D.; Bosaeus, I.; Bruera, E.; Fainsinger, R.L.; Jatoi, A.; Loprinzi, C.; MacDonald, N.; Mantovani, G.; et al. Definition and classification of cancer cachexia: An international consensus. *Lancet Oncol. 2011*, 12, 489–495. [CrossRef]

26. Pipek, L.Z.; Baptista, C.G.; Nascimento, R.F.V.; Taba, J.V.; Suzuki, M.O.; do Nascimento, F.S.; Martines, D.R.; Nii, F.; Iuamoto, E. Robotic kidney transplantation in the obese patient: 10-year experience from a single center. *Transplantation 2014*, 98, 167–176. [CrossRef]

27. Theodorakopoulos, M.P.; Boutou, A.K.; Pella, E.; Alexandrou, M.E.; Patoulias, D.; Kassimatis, E.; Diplas, K.; Papagianni, A.; Sarafidis, P.A. Cardiorespiratory fitness in kidney transplant recipients compared to patients with kidney failure: A systematic review and meta-analysis. *Transpl. Int. 2021*, 34, 1801–1811. [CrossRef]

28. Nicoletto, B.B.; Fonseca, N.K.; Manfro, R.C.; Gonçalves, L.F.; Leitão, C.B.; Souza, G.C. Effects of obesity on kidney transplantation outcomes: A systematic review and meta-analysis. *Transplantation 2014*, 98, 167–176. [CrossRef]

29. Tzvetanov, I.G.; Spaggiari, M.; Tulla, K.A.; Di Bella, C.; Okoye, O.; Di Cocco, P.; Jeon, H.; Oberholzer, J.; Giulianiotti, P.C.; Benedetti, E. Robotic kidney transplantation in the obese patient: 10-year experience from a single center. *Am. J. Transplant. 2020*, 20, 430–440. [CrossRef]

30. Manabe, S.; Kataoka, H.; Mochizuki, T.; Iwadoh, K.; Ushio, Y.; Kawachi, K.; Watanabe, K.; Watanabe, S.; Akihisa, T.; Makabe, S.; et al. Impact of visceral fat area in patients with chronic kidney disease. *Clin. Exp. Nephrol. 2021*, 25, 608–620. [CrossRef]

31. Fried, L.P.; Kronmal, R.A.; Newman, A.B.; Bild, D.E.; Mittelmark, M.B.; Polak, J.F.; Robbins, J.A.; Gardin, J.M. Risk factors for 5-year mortality in older adults: The Cardiovascular Health Study. *JAMA 1998*, 279, 585–592. [CrossRef] [PubMed]

32. Pinter, J.; Hansen, C.S.; Chapman, J.R.; Wong, G.; Craig, J.C.; Schell, J.O.; Tong, A. Perspectives of Older Kidney Transplant Recipients on Kidney Transplantation. *Clin. J. Am. Soc. Nephrol. 2017*, 12, 443–453. [CrossRef] [PubMed]
33. Scherbakov, N.; Pietrock, C.; Sandek, A.; Ebner, N.; Valentova, M.; Springer, J.; Schefold, J.C.; von Haehling, S.; Anker, S.D.; Norman, K.; et al. Body weight changes and incidence of cachexia after stroke. *J. Cachexia Sarcopenia Muscle* 2019, 10, 611–620. [CrossRef] [PubMed]

34. Ratnayake, C.B.; Loveday, B.P.; Shrikhande, S.V.; Windsor, J.A.; Pandanaboyana, S. Impact of preoperative sarcopenia on postoperative outcomes following pancreatic resection: A systematic review and meta-analysis. *Pancreatology* 2018, 18, 996–1004. [CrossRef] [PubMed]

35. Britton, K.A.; Massaro, J.M.; Murabito, J.M.; Kreger, B.E.; Hoffmann, U.; Fox, C.S. Body fat distribution, incident cardiovascular disease, cancer, and all-cause mortality. *J. Am. Coll. Cardiol.* 2013, 62, 921–925. [CrossRef]

36. Williams, G.R.; Muss, H.B.; Shachar, S.S. Cachexia in patients with cancer. *Lancet Oncol.* 2016, 17, e220. [CrossRef]

37. Weerink, L.B.M.; van der Hoorn, A.; van Leeuwen, B.L.; de Bock, G.H. Low skeletal muscle mass and postoperative morbidity in surgical oncology: A systematic review and meta-analysis. *J. Cachexia Sarcopenia Muscle* 2020, 11, 636–649. [CrossRef]

38. Faron, A.; Sprinkart, A.M.; Kuetting, D.L.R.; Feisst, A.; Isaak, A.; Endler, C.; Chang, J.; Nowak, S.; Block, W.; Thomas, D.; et al. Body composition analysis using CT and MRI: Intra-individual intermodal comparison of muscle mass and myosteatosis. *Sci. Rep.* 2020, 10, 11765. [CrossRef]

39. Rollins, K.E.; Awwad, A.; Macdonald, I.A.; Lobo, D.N. A comparison of two different software packages for analysis of body composition using computed tomography images. *Nutrition* 2019, 57, 92–96. [CrossRef]

40. Wang, B.; Torriani, M. Artificial Intelligence in the Evaluation of Body Composition. *Semin. Musculoskelet. Radiol.* 2020, 24, 30–37. [CrossRef]